On May 2, 2024, health tech company Transcarent announced a $126 million Series D funding round led by General Catalyst and 7wireVentures, with participation from investors Geodesic Capital, Memorial Hermann Health System, Threshold Ventures, Kinnevik, Ally Bridge Group, Human Capital, Merck Global Health Innovation Fund, Alta Partners, and Leaps by Bayer. This latest investment brings total funding raised to approximately $450 million from a diverse group of investors at a valuation of $2.2 billion. Wilson Sonsini Goodrich & Rosati advised Transcarent on the transaction.

Transcarent’s industry leading health and care platform makes it easy for people to access care and employers to provide and pay for the care. It is the only platform that brings together medical, surgery, pharmacy, and mental health care into one place. The additional investments will be leveraged to accelerate AI capabilities, support commercial growth, and for strategic growth opportunities.

The Wilson Sonsini team that advised Transcarent included Mark Baudler, Lianna Whittleton, Angela Loc, Amanda Creedon, Lindsey Berger, and Laura Odujinrin.

For more information, please see Transcarent’s press release. Additional coverage can be found on Reuters and Fierce Healthcare.